The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform
Sota Oguro - One of the best experts on this subject based on the ideXlab platform.
-
transcatheter arterial embolization using imipenem cilastatin sodium for tendinopathy and Enthesopathy refractory to nonsurgical management
Journal of Vascular and Interventional Radiology, 2013Co-Authors: Yuji Okuno, Noboru Matsumura, Sota OguroAbstract:Purpose: To evaluate the feasibility and effects of transcatheter arterial embolization with imipenem/cilastatin sodium (CS) to treat tendinopathy and Enthesopathy that are refractory to traditional nonsurgical management. Materials and Methods: Transcatheter arterial embolization with imipenem/CS as an embolic agent was performed in seven patients (five men; mean age, 51.7 y) with tendinopathy and Enthesopathy (patellar tendinopathy, n ¼ 1; rotator cuff tendinopathy, n ¼ 2; plantar fasciitis, n ¼ 1; lateral epicondylitis, n ¼ 1; iliotibial band syndrome, n ¼ 1; and Achilles insertion tendinopathy, n ¼ 1). All patients had unrelenting pain at the site of tendinopathy and Enthesopathy before the procedure. Technical success, adverse events, and changes in visual analog scale (VAS) scores were assessed. Results: All procedures were technically successful, and no major adverse events developed. Compared with before the procedure, mean VAS scores were significantly decreased at 1 day, 1 week, and 1 and 4 months after the procedure (72.7 mm 9.9 vs 17.4 mm 18.5, 16.0 mm 18.1, 13.7 mm 7.3, and 9.7 mm 6.8, respectively; all P o .001). Conclusions: Transcatheter arterial embolization with imipenem/CS was feasible and effectively relieved unrelenting pain associated with tendinopathy and Enthesopathy.
-
Transcatheter arterial embolization using imipenem/cilastatin sodium for tendinopathy and Enthesopathy refractory to nonsurgical management.
Journal of vascular and interventional radiology : JVIR, 2013Co-Authors: Yuji Okuno, Noboru Matsumura, Sota OguroAbstract:Purpose: To evaluate the feasibility and effects of transcatheter arterial embolization with imipenem/cilastatin sodium (CS) to treat tendinopathy and Enthesopathy that are refractory to traditional nonsurgical management. Materials and Methods: Transcatheter arterial embolization with imipenem/CS as an embolic agent was performed in seven patients (five men; mean age, 51.7 y) with tendinopathy and Enthesopathy (patellar tendinopathy, n ¼ 1; rotator cuff tendinopathy, n ¼ 2; plantar fasciitis, n ¼ 1; lateral epicondylitis, n ¼ 1; iliotibial band syndrome, n ¼ 1; and Achilles insertion tendinopathy, n ¼ 1). All patients had unrelenting pain at the site of tendinopathy and Enthesopathy before the procedure. Technical success, adverse events, and changes in visual analog scale (VAS) scores were assessed. Results: All procedures were technically successful, and no major adverse events developed. Compared with before the procedure, mean VAS scores were significantly decreased at 1 day, 1 week, and 1 and 4 months after the procedure (72.7 mm 9.9 vs 17.4 mm 18.5, 16.0 mm 18.1, 13.7 mm 7.3, and 9.7 mm 6.8, respectively; all P o .001). Conclusions: Transcatheter arterial embolization with imipenem/CS was feasible and effectively relieved unrelenting pain associated with tendinopathy and Enthesopathy.
Yuji Okuno - One of the best experts on this subject based on the ideXlab platform.
-
transcatheter arterial embolization using imipenem cilastatin sodium for tendinopathy and Enthesopathy refractory to nonsurgical management
Journal of Vascular and Interventional Radiology, 2013Co-Authors: Yuji Okuno, Noboru Matsumura, Sota OguroAbstract:Purpose: To evaluate the feasibility and effects of transcatheter arterial embolization with imipenem/cilastatin sodium (CS) to treat tendinopathy and Enthesopathy that are refractory to traditional nonsurgical management. Materials and Methods: Transcatheter arterial embolization with imipenem/CS as an embolic agent was performed in seven patients (five men; mean age, 51.7 y) with tendinopathy and Enthesopathy (patellar tendinopathy, n ¼ 1; rotator cuff tendinopathy, n ¼ 2; plantar fasciitis, n ¼ 1; lateral epicondylitis, n ¼ 1; iliotibial band syndrome, n ¼ 1; and Achilles insertion tendinopathy, n ¼ 1). All patients had unrelenting pain at the site of tendinopathy and Enthesopathy before the procedure. Technical success, adverse events, and changes in visual analog scale (VAS) scores were assessed. Results: All procedures were technically successful, and no major adverse events developed. Compared with before the procedure, mean VAS scores were significantly decreased at 1 day, 1 week, and 1 and 4 months after the procedure (72.7 mm 9.9 vs 17.4 mm 18.5, 16.0 mm 18.1, 13.7 mm 7.3, and 9.7 mm 6.8, respectively; all P o .001). Conclusions: Transcatheter arterial embolization with imipenem/CS was feasible and effectively relieved unrelenting pain associated with tendinopathy and Enthesopathy.
-
Transcatheter arterial embolization using imipenem/cilastatin sodium for tendinopathy and Enthesopathy refractory to nonsurgical management.
Journal of vascular and interventional radiology : JVIR, 2013Co-Authors: Yuji Okuno, Noboru Matsumura, Sota OguroAbstract:Purpose: To evaluate the feasibility and effects of transcatheter arterial embolization with imipenem/cilastatin sodium (CS) to treat tendinopathy and Enthesopathy that are refractory to traditional nonsurgical management. Materials and Methods: Transcatheter arterial embolization with imipenem/CS as an embolic agent was performed in seven patients (five men; mean age, 51.7 y) with tendinopathy and Enthesopathy (patellar tendinopathy, n ¼ 1; rotator cuff tendinopathy, n ¼ 2; plantar fasciitis, n ¼ 1; lateral epicondylitis, n ¼ 1; iliotibial band syndrome, n ¼ 1; and Achilles insertion tendinopathy, n ¼ 1). All patients had unrelenting pain at the site of tendinopathy and Enthesopathy before the procedure. Technical success, adverse events, and changes in visual analog scale (VAS) scores were assessed. Results: All procedures were technically successful, and no major adverse events developed. Compared with before the procedure, mean VAS scores were significantly decreased at 1 day, 1 week, and 1 and 4 months after the procedure (72.7 mm 9.9 vs 17.4 mm 18.5, 16.0 mm 18.1, 13.7 mm 7.3, and 9.7 mm 6.8, respectively; all P o .001). Conclusions: Transcatheter arterial embolization with imipenem/CS was feasible and effectively relieved unrelenting pain associated with tendinopathy and Enthesopathy.
Raghey Kurien - One of the best experts on this subject based on the ideXlab platform.
-
A severe case of Enthesopathy mimicking intertrochanteric fractures on Tc-99m MDP scan.
Clinical nuclear medicine, 2004Co-Authors: Kottekkattu Balan, Raghey KurienAbstract:Enthesopathy or enthesitis refers to inflammation at the sites of ligamentous and tendinous insertions onto bone. Clinically, this manifests as pain, with or without swelling, at the entheses. The most common site of involvement is the calcaneum where the Achilles tendon and plantar fascia are inserted. Other sites include the fingers, toes, symphysis pubis, ischium, iliac crest, and femoral trochanters. Radiologically, Enthesopathy is suggested by the development of erosions and reactive new bone formation. Classic appearances of plantar fasciitis on a Tc-99m MDP bone scintigram are well known but there is a paucity of similar information in other areas affected by this condition. The authors describe a case of severe Enthesopathy, which mimicked intertrochanteric fractures on the bone scan. The typical bone tracer distribution, including involvement of other areas, and a normal contemporaneous radiograph were helpful to exclude trauma.
Noboru Matsumura - One of the best experts on this subject based on the ideXlab platform.
-
transcatheter arterial embolization using imipenem cilastatin sodium for tendinopathy and Enthesopathy refractory to nonsurgical management
Journal of Vascular and Interventional Radiology, 2013Co-Authors: Yuji Okuno, Noboru Matsumura, Sota OguroAbstract:Purpose: To evaluate the feasibility and effects of transcatheter arterial embolization with imipenem/cilastatin sodium (CS) to treat tendinopathy and Enthesopathy that are refractory to traditional nonsurgical management. Materials and Methods: Transcatheter arterial embolization with imipenem/CS as an embolic agent was performed in seven patients (five men; mean age, 51.7 y) with tendinopathy and Enthesopathy (patellar tendinopathy, n ¼ 1; rotator cuff tendinopathy, n ¼ 2; plantar fasciitis, n ¼ 1; lateral epicondylitis, n ¼ 1; iliotibial band syndrome, n ¼ 1; and Achilles insertion tendinopathy, n ¼ 1). All patients had unrelenting pain at the site of tendinopathy and Enthesopathy before the procedure. Technical success, adverse events, and changes in visual analog scale (VAS) scores were assessed. Results: All procedures were technically successful, and no major adverse events developed. Compared with before the procedure, mean VAS scores were significantly decreased at 1 day, 1 week, and 1 and 4 months after the procedure (72.7 mm 9.9 vs 17.4 mm 18.5, 16.0 mm 18.1, 13.7 mm 7.3, and 9.7 mm 6.8, respectively; all P o .001). Conclusions: Transcatheter arterial embolization with imipenem/CS was feasible and effectively relieved unrelenting pain associated with tendinopathy and Enthesopathy.
-
Transcatheter arterial embolization using imipenem/cilastatin sodium for tendinopathy and Enthesopathy refractory to nonsurgical management.
Journal of vascular and interventional radiology : JVIR, 2013Co-Authors: Yuji Okuno, Noboru Matsumura, Sota OguroAbstract:Purpose: To evaluate the feasibility and effects of transcatheter arterial embolization with imipenem/cilastatin sodium (CS) to treat tendinopathy and Enthesopathy that are refractory to traditional nonsurgical management. Materials and Methods: Transcatheter arterial embolization with imipenem/CS as an embolic agent was performed in seven patients (five men; mean age, 51.7 y) with tendinopathy and Enthesopathy (patellar tendinopathy, n ¼ 1; rotator cuff tendinopathy, n ¼ 2; plantar fasciitis, n ¼ 1; lateral epicondylitis, n ¼ 1; iliotibial band syndrome, n ¼ 1; and Achilles insertion tendinopathy, n ¼ 1). All patients had unrelenting pain at the site of tendinopathy and Enthesopathy before the procedure. Technical success, adverse events, and changes in visual analog scale (VAS) scores were assessed. Results: All procedures were technically successful, and no major adverse events developed. Compared with before the procedure, mean VAS scores were significantly decreased at 1 day, 1 week, and 1 and 4 months after the procedure (72.7 mm 9.9 vs 17.4 mm 18.5, 16.0 mm 18.1, 13.7 mm 7.3, and 9.7 mm 6.8, respectively; all P o .001). Conclusions: Transcatheter arterial embolization with imipenem/CS was feasible and effectively relieved unrelenting pain associated with tendinopathy and Enthesopathy.
Carolyn M. Macica - One of the best experts on this subject based on the ideXlab platform.
-
Mineralizing Enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in Hyp mice
Seminars in Arthritis and Rheumatism, 2013Co-Authors: Carolyn M. Macica, Andrew C. Karaplis, Xiuying Bai, Shyam Desai, Jean-pierre FaletAbstract:Enthesopathy is a common feature of X-linked hypophosphatemia (XLH). We have previously shown that the Enthesopathy is recapitulated in Hyp mice, a murine model of XLH, and is characterized by significant hyperplasia of mineralizing fibrochondrocytes that coexpress FGFR3/klotho. It is unclear, however, whether it occurs in other forms of renal phosphate-wasting disorders attributable to high FGF23 levels and what is the underlying pathophysiology. Here, we describe two brothers of Lebanese origin with autosomal-recessive hypophosphatemic rickets (ARHR) due to the Met1Val (M1V) mutation in dentin matrix acidic phosphoprotein 1 (DMP1). In addition to the biochemical and skeletal features of long-standing rickets with elevated FGF23 levels, these individuals exhibited severe, debilitating, generalized Enthesopathy. These data suggest that mineralizing Enthesopathy is a feature common to phosphate-wasting disorders mediated by FGF23. To address this possibility, we examined a murine model of FGF23 overexpression using a transgene encoding the secreted form of human FGF23 (R176Q) cDNA (FGF23-TG mice). Mice have a biochemical profile and phenotypic traits akin to phosphate-wasting disorders attributed to FGF23. We report that FGF23-TG mice display a similar mineralizing Enthesopathy of the Achilles and plantar facial insertions evident by 12 weeks, the period of developmental maturity. The Enthesopathy (expressed as a percentage of total enthesis area) is characterized by an expansion of alkaline phosphatase-positive fibrochondrocytes embedded in a mineralized matrix (wild-type mice, 0.75 ± 0.5%; FGF23-TG mice, 15.1 ± 3.4%, p p
-
Mineralizing Enthesopathy Is a Common Feature of Renal Phosphate-Wasting Disorders Attributed to FGF23 and Is Exacerbated by Standard Therapy in Hyp Mice
Endocrinology, 2012Co-Authors: Andrew C. Karaplis, Xiuying Bai, Jean-pierre Falet, Carolyn M. MacicaAbstract:We have previously confirmed a paradoxical mineralizing Enthesopathy as a hallmark of X-linked hypophosphatemia. X-linked hypophosphatemia is the most common of the phosphate-wasting disorders mediated by elevated fibroblast growth factor 23 (FGF23) and occurs as a consequence of inactivating mutations of the PHEX gene product. Despite childhood management of the disease, these complications of tendon and ligament insertion sites account for a great deal of the disease's morbidity into adulthood. It is unclear whether the Enthesopathy occurs in other forms of renal phosphate-wasting disorders attributable to high FGF23 levels. Here we describe two patients with autosomal recessive hypophosphatemic rickets due to the Met1Val mutation in dentin matrix acidic phosphoprotein 1 (DMP1). In addition to the biochemical and skeletal features of long-standing rickets with elevated FGF23 levels, these individuals exhibited severe, debilitating, generalized mineralized Enthesopathy. These data suggest that enthesophy...